In their report, Lee et al.[13] hypothesized that the upstream EGFR pathway could also serve as a resistance mechanism and that inhibition of EGFR would enhance the anti-tumor activity of the CHK1 inhibitor prexasertib in triple-negative breast cancer. This evidence concerns the gene CHEK1 and triple-negative breast carcinoma.